Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Cash & Current Investments: 2016-2025

Historic Cash & Current Investments for Tg Therapeutics (TGTX) over the last 10 years, with Sep 2025 value amounting to $235.8 million.

  • Tg Therapeutics' Cash & Current Investments fell 30.86% to $235.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 38.88%. This contributed to the annual value of $311.0 million for FY2024, which is 42.98% up from last year.
  • As of Q3 2025, Tg Therapeutics' Cash & Current Investments stood at $235.8 million, which was down 41.29% from $401.6 million recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Cash & Current Investments peaked at $523.8 million during Q1 2021, and registered a low of $139.7 million during Q1 2023.
  • For the 3-year period, Tg Therapeutics' Cash & Current Investments averaged around $260.7 million, with its median value being $229.2 million (2023).
  • Its Cash & Current Investments has fluctuated over the past 5 years, first skyrocketed by 568.73% in 2021, then slumped by 55.87% in 2022.
  • Tg Therapeutics' Cash & Current Investments (Quarterly) stood at $314.8 million in 2021, then plummeted by 48.64% to $161.7 million in 2022, then soared by 34.53% to $217.5 million in 2023, then skyrocketed by 42.98% to $311.0 million in 2024, then plummeted by 30.86% to $235.8 million in 2025.
  • Its last three reported values are $235.8 million in Q3 2025, $401.6 million for Q2 2025, and $420.3 million during Q1 2025.